|  |  |  |  |
| --- | --- | --- | --- |
| **Organization** | **Country** | **Short Description** | **Session** |
| **Comphya**Rodrigo Fraga-Silva | Switzerland | Comphya is a Swiss medical device company, spin-off from the Swiss Federal Institute of Technology (EPFL). Its mission is to overcome the major clinical problems of erectile dysfunction (ED) in spinal cord injury and post-prostatectomy patients. Our innovation lies on neuroprosthetics principles and will offer a unique and superior treatment for ED. Our goal is to fulfill patient needs through safe and effective medical devices, offering life quality in large parts of the malepopulation in great need.<https://www.comphya.com/>  | Theme Healthtech: Medical Devices II |
| **c-LEcta GmbH**Marc Struhalla | Germany | c-LEcta is one of the world’s leading industrial biotechnology companies located in Leipzig, Germany. The company develops and implements innovative new production technologies with a focus on applications in the pharma, feed and food industries. The technological core competence of c-LEcta is enzyme and strain engineering. The company covers a broad range of the value chain from product development, via scale-up and commercial scale production to productapprovals and supply. <https://www.c-lecta.com/>  | Theme Foodtech |
| **Fineheart**Stephane Garrigue | France | FineHeart was founded by a team of four internationally renowned cardiac surgeons and cardiologists, led by Dr. Stephane Garrigue (ICOMS Inventor) and Dr. Philippe Ritter, co-inventor of cardiac resynchronization therapy, with a vision of making a miniaturized, fully implantable, pulsatile circulatory support system that would overcome many of the challenges associated with left ventricularassist devices (LVADs) currently on market. <http://www.fine-heart.com>  | Theme Healthtech: Medical Devices |
| **GALGO MEDICAL**Antoni Riu | Spain | Galgo Medical creates predictive value for medical practitioners to design personalized treatment strategies for patients based on imaging software. We apply it to 3: arrhythmia care to stratify ICD implantation and its eventual ablation; osteoporosis predicting risk of fracture; & endovascular treatment with stents planning their deployment. The business model is based on licensing the IP &contracts with industry.<https://www.galgomedical.com/en/>  | Theme Healthtech: Digital Imaging & Digital Health |
| **Noscendo GmbH**Philip Stevens | Germany | Sepsis is a disease with high case numbers, high mortality and extremely high healthcare cost. Blood culture as the gold standard for sepsis diagnosis has severe disadvantages. To overcome these, one has to recognize and diagnose most reliably the infecting agent to successfully treat the infected patient. <http://noscendo.com/>  | Theme Healthtech: Diagnostics |
| **OncoLize BV**Mike de Leeuw | Netherlands | Based on established hydrogel technology by InGell Labs, we develop a pipeline of injectable drug depots, releasing generic chemo compounds into solid tumoursover weeks to months. <https://oncolize.com/>  | Theme Healthtech: Biotech |
| **ONTOFORCE**Hans Constandt | Belgium | ONTOFORCE was founded in 2011 helping finding the right data for children with learning disorders and disabilities. In 2013 this technology got access to Healthcare and Life sciences bringing data from patients and research together.<https://www.ontoforce.com/>   | Theme Healthtech: Online Hospitals & Data4Health |

|  |  |  |  |
| --- | --- | --- | --- |
| **Question ai**Bart Stevens | Belgium | Using Micro Moments (e.g. unlock moment of your smartphone, checking smartwatch, using Alexa) we are able to ask numerous relevant questions to patients in different statuses of their recovery proces. So for we have been able to capture +/- 600.000 data points (answers to questions) with our customers.<http://www.questions.ai/>  | Theme Healthtech: Connected Health |
| **Syndivia**Sasha Koniev | France | Syndivia develops a pipeline of innovative cancer therapies through both in-house and partnered programs. Syndivia’s lead product SDV1001 is an albumin binding prodrug that releases a cytotoxic agent exclusively in the tumor environment. Early preclinical studies have demonstrated an outstanding efficacy of SDV1001 in animal models with breast and pancreatic cancer. Furthermore, SDV1001 is potentially applicable in a wide variety of cancer indications, includinglung, breast, and gastrointestinal tract carcinomas.<http://www.syndivia.com/>  | Theme Healthtech: Therapeutics |
|  |  |  |  |